Protonated trititanate nanotubes: an efficient catalyst for one-pot three-component coupling of benzothiazole amines, heterocyclic aldehydes, and dialkyl/diaryl phosphites with a greener perspective
Nano-size catalysts of TiO2, ZnO, CuO, and protonated trititanate nanotubes (H2Ti3O7) have been investigated for the one-pot three component synthesis of novel α-aminophosphonates from benzothiazole amines, heteroaldehydes, and dialkyl/diaryl phosphites via Kabachnik–Fieldsreaction. This methodology provides a new and convenient approach to multicomponent reaction and the H2Ti3O7 nanotubes catalyst is recyclable
研究了TiO 2,ZnO,CuO和质子化三钛酸盐纳米管(H 2 Ti 3 O 7)的纳米尺寸催化剂,用于由苯并噻唑胺,杂醛和二烷基/二芳基化合物一锅三组分合成新型α-氨基膦酸酯。通过Kabachnik-Fields反应生成亚磷酸酯。这种方法为多组分反应提供了一种新的便捷方法,H 2 Ti 3 O 7纳米管催化剂可循环使用多达七个循环。
Camphor-derived thioureas: Synthesis and application in asymmetric Kabachnik-Fields reaction
Abstract A series of camphor-derived thiourea organocatalysts 3a–f were designed and synthesized from (1 R ,3 S )-camphoric acid 1 and applied to the one-potthree-component Kabachnik–Fields reaction. Catalyst 3c was found to be an efficientorganocatalyst for the reaction of 2-cyclopropylpyrimidin-4-carbaldehyde 4 , various amines 5, and diphenylphosphite 6 to yield the corresponding enantioselective
Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)
作者:Kentaro Futatsugi、Daniel W. Kung、Suvi T. M. Orr、Shawn Cabral、David Hepworth、Gary Aspnes、Scott Bader、Jianwei Bian、Markus Boehm、Philip A. Carpino、Steven B. Coffey、Matthew S. Dowling、Michael Herr、Wenhua Jiao、Sophie Y. Lavergne、Qifang Li、Ronald W. Clark、Derek M. Erion、Kou Kou、Kyuha Lee、Brandon A. Pabst、Sylvie M. Perez、Julie Purkal、Csilla C. Jorgensen、Theunis C. Goosen、James R. Gosset、Mark Niosi、John C. Pettersen、Jeffrey A. Pfefferkorn、Kay Ahn、Bryan Goodwin
DOI:10.1021/acs.jmedchem.5b01006
日期:2015.9.24
The medicinal chemistry and preclinical biology of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2) is described. A screening hit 1 with low lipophilic efficiency (LipE) was optimized through two key structural modifications: (1) identification of the pyrrolidine amide group for a significant LipE improvement, and (2) insertion of a sp(3)-hybridized carbon center in the core of the molecule for simultaneous improvement of N-glucuronidation metabolic liability and off-target pharmacology. The preclinical candidate 9 (PF-06424439) demonstrated excellent ADMET properties and decreased circulating and hepatic lipids when orally administered to dyslipidemic rodent models.